Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol - Wikidata - wikimedia - TriplyDB

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol

http://www.wikidata.org/entity/Q34117111

about

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial Is the state of health of rheumatoid arthritis patients receiving adequate treatment, predictable? - Results of a survey.Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic a Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.Work productivity in rheumatoid arthritis: relationship with clinical and radiological features.Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.Certolizumab pegol in axial spondyloarthritis.Patient-reported outcomes in core domain sets for rheumatic diseases.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic.Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria.Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis.Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.Productivity loss of Japanese patients with rheumatoid arthritis - A cross-sectional survey.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.

P2860

Q24193535-2CD9B3B5-78A5-4FD8-81A9-206714CC9233 Q34485175-77EC8D08-8B29-4EBE-A45B-C98CAFA9BD77 Q35351313-FDC45627-AE1D-463D-9C42-B73DE01A323D Q35595158-FF604926-0EBA-467D-AE9B-5A07DF4AC1C6 Q35664666-9555776A-A0A4-4A31-8C53-8C91358720FD Q36252760-6518B3E4-B3D7-4C00-82C9-C97E51E7AAFD Q36327384-D7379E33-5096-471F-AF9A-0FEC20E06507 Q36505055-2A632283-B802-4B2E-8159-BCF3FA9FACC6 Q36866954-2F8AF531-E333-494D-AD6C-85F234404663 Q37391811-4734052C-40B2-4D6B-96C1-361D2D45A766 Q38010365-F0E41950-B621-437C-A15A-0518D1C059DC Q38075801-B01CFBEB-9C0C-4A02-91B7-1B47BA15DA83 Q38161555-C514137B-4F0E-454A-84AD-0D757D562032 Q38577796-1509B44B-77C3-4F02-A533-288B7B7EDB24 Q38972531-72DF965D-C8A6-4334-847C-76D4F3695EAD Q39113622-DE785BCE-B7C2-4CC6-A106-E5DEF5F43239 Q39568753-6091541E-5CE9-4988-9AD8-9FA314455FEA Q39694655-486816BB-2CE5-4D9B-B7F1-D0E7325FBE07 Q40847456-1F05461B-414F-4A9C-9FDD-652261A4FB68 Q40926392-41FD1C26-C9C3-4374-ACEB-C2F7DF08FEBA Q47563427-8C6F8C92-2A47-4DE1-A4F8-14E207F8AD9A Q47784999-EE7BAEE3-6BE5-4BF7-9150-3A9377B20EDD Q47836056-29C6FF28-8363-4CC5-8D62-647E34BAE241 Q52642359-26A81BBF-2C07-4ECA-B047-A4AC4CB1B4CB Q55098455-83B8155F-E637-42DB-9C28-752F553E7456

P2860

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol

http://www.wikidata.org/entity/Q34117111

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Physical function improvements ...... reated with certolizumab pegol

@ast

Physical function improvements ...... reated with certolizumab pegol

@en

Physical function improvements ...... reated with certolizumab pegol

@nl

type

label

Physical function improvements ...... reated with certolizumab pegol

@ast

Physical function improvements ...... reated with certolizumab pegol

@en

Physical function improvements ...... reated with certolizumab pegol

@nl

prefLabel

Physical function improvements ...... reated with certolizumab pegol

@ast

Physical function improvements ...... reated with certolizumab pegol

@en

Physical function improvements ...... reated with certolizumab pegol

@nl

P1433

Q34117111-203FB00B-F09D-4B00-BDEF-E0385245D50A

P1476

Q34117111-D5B55320-BE15-4F33-9534-86EAB43645D4

P2093

Q34117111-2FBCEBA0-6501-4D05-97E9-07C5BAE3962D

Q34117111-A3067CAE-238C-4A98-96DD-D50B9B6AE66D

Q34117111-BFBB441A-EDDF-4AD8-BACF-2826F4F3EE8E

Q34117111-D527E6D1-DCA4-4666-B2A6-E66F2B59785F

Q34117111-F999BA2F-5708-4C1E-8BA3-49AA15D4BA71

Q34117111-FAF4A321-25FD-46B7-84AA-6C74E17DDA02

P2860

Q34117111-04F2D273-7A19-4750-A0F9-E8A71BFD7A0A

Q34117111-1B7003EF-9D84-44B6-AC14-98926BF93A31

Q34117111-1F1972BE-7D89-421A-981E-81F6E5908241

Q34117111-2183A09E-C953-41BC-B920-17D29C42B052

Q34117111-2FC604AC-3B70-429E-841B-F47C95B6BC5A

Q34117111-365B62DC-9487-49E1-B873-B8798AE6EA29

Q34117111-38F489F6-3738-4764-9A8D-2E95C4C744A9

Q34117111-3BDE555B-BA72-4727-B0CD-82A8DF93D051

Q34117111-42EB2856-11C2-491A-B07A-77395A93A9EF

Q34117111-46012921-E67A-4299-A6C7-C48E128C817C

P304

Q34117111-10EC8780-206B-4BDA-BC37-7A5A7DDF79FA

P31

Q34117111-B61322AA-EC1B-4074-B00A-5525B3222914

P356

Q34117111-75D64BE6-8B0E-439A-833A-B64BAA2AC907

P433

Q34117111-B204C623-5F4B-45FB-BDAB-7EA7C6407D9E

P478

Q34117111-37BF3400-6515-43DC-A7A2-BB04F7AAFB31

P577

Q34117111-DB030872-FAFB-482C-9226-B0A3EE3EC6FF

P5875

Q34117111-FACD3704-6EA6-4412-8392-7D33837DF429

P698

Q34117111-38E8DFE9-8B32-4367-8D65-343B4C93A3CF

P932

Q34117111-3C7AC601-1E71-48F4-9A74-D547E3F0A91D

P356

P1433

P1476

Physical function improvements ...... reated with certolizumab pegol

@en

P2093

Geoffroy Coteur

http://www.w3.org/2001/XMLSchema#string

Johanna M Hazes

http://www.w3.org/2001/XMLSchema#string

Oana Purcaru

http://www.w3.org/2001/XMLSchema#string

Peter Taylor

http://www.w3.org/2001/XMLSchema#string

Philip Mease

http://www.w3.org/2001/XMLSchema#string

Vibeke Strand

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of cost data in randomized trials: an application of the non-parametric bootstrap.

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont

Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS).

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis.

Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys.

Arthritis and employment research: where are we? Where do we need to go?

Systematic review of studies of productivity loss due to rheumatoid arthritis.

Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use.

P304

1900-1910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEQ109

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44672839

http://www.w3.org/2001/XMLSchema#string

P698

20547658

http://www.w3.org/2001/XMLSchema#string

P932

2936945

http://www.w3.org/2001/XMLSchema#string